Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Celgene

American biopharmaceutical company

Celgene    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Celgene: American biopharmaceutical company
Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS.

0
shares
ShareTweetSavePostSend
 

No news matches found

Sorry, we were unable to find any results in our database for your query


Free news archive access


Did you know?
You are eligible to search our news archive with millions of news references free of charge.

To do this, please sign in first at the top of the screen.

Information about free access to our news archive


Search this site and the web:


Free news archive

You Might Like


Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.